Who Paid My Doc
Joseph Beck
Hematology & Oncology Fayetteville, AR Medical Doctor
NPI 1952372120 CMS profile 361392
3232 N Northhills Blvd, Fayetteville, AR 72703
General payments
$21,763
Research payments
$91,941
Ownership & investment interest
$0
Research they led as principal investigator
$33,779,419
Through program year 2025, Joseph Beck of Fayetteville, AR is reported in the CMS Open Payments database as having received $21,763 across 562 general payments and $91,941 in research payments paid to them. Separately, studies naming them as principal investigator received $33,779,419 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
14 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $8,526 | 86 | |
| 2025 | Research | $1,544 | 3 | |
| 2024 | General | $3,422 | 121 | |
| 2024 | Research | $4,090 | 4 | |
| 2023 | General | $1,881 | 96 | |
| 2023 | Research | $7,579 | 10 | |
| 2022 | General | $923 | 59 | |
| 2022 | Research | $50,973 | 15 | |
| 2021 | General | $975 | 56 | |
| 2021 | Research | $2,220 | 4 | |
| 2020 | General | $4,576 | 60 | |
| 2020 | Research | $31 | 1 | |
| 2019 | General | $1,460 | 84 | |
| 2019 | Research | $25,503 | 4 |
Beside peers
- Joseph Beck
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Joseph Beck were reported at $8,526. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Joseph Beck | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,460 | $529 | $121–$2,516 | $163 |
| 2020 | $4,576 | $339 | $82–$2,213 | $114 |
| 2021 | $975 | $263 | $49–$1,965 | $132 |
| 2022 | $923 | $416 | $103–$2,395 | $149 |
| 2023 | $1,881 | $542 | $125–$2,646 | $160 |
| 2024 | $3,422 | $692 | $141–$3,008 | $164 |
| 2025 | $8,526 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 47 drugsPart D claims
1,624
Drug cost
$3,171,307
Branded share of claims
22.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | Brand | 69 | $1,110,199 | |
| Revlimid Lenalidomide | Brand | 42 | $799,674 | |
| Brukinsa Zanubrutinib | Brand | 32 | $458,378 | |
| Kisqali Ribociclib Succinate | Brand | 20 | $277,572 | |
| Calquence Acalabrutinib Maleate | Brand | 14 | $217,573 | |
| Verzenio Abemaciclib | Brand | 12 | $188,563 | |
| Imbruvica Ibrutinib | Brand | 13 | $75,800 | |
| Xarelto Rivaroxaban | Brand | 27 | $20,403 | |
| Anastrozole | Generic | 230 | $4,086 | |
| Letrozole | Generic | 226 | $3,731 |
The 10 drugs with the highest cost, of 47 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 310 billing codesPaid by Medicare
$4,075,710
Medicare patients
1,460
Services billed
234,766
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Cancer | 58% | |
| Arthritis | 46% | |
| Ischemic heart disease | 32% | |
| Diabetes | 27% | |
| Depression | 26% | |
| Chronic kidney disease | 24% | |
| COPD | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 36 | 13,800 | $620,040 |
| Injection, nivolumab, 1 mg J9299 | Office | 22 | 12,560 | $311,012 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 14 | 7,200 | $282,162 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg J1561 | Office | 44 | 7,168 | $272,457 |
| Injection, denosumab, 1 mg J0897 | Office | 54 | 6,720 | $137,679 |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg Q5123 | Office | 24 | 2,720 | $86,063 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 27 | 2,700 | $43,363 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 | Office | 40 | 3,997 | $25,192 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 20 | 77 | $10,575 |
| Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram Q5125 | Office | 19 | 10,320 | $3,835 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 40 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| KISQALI |
|
$1,311 | 20 | — |
| ENHERTU |
|
$202 | — | — |
| ORGOVYX |
|
$197 | — | — |
| PLUVICTO |
|
$116 | — | — |
| IMFINZI |
|
$112 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 40 with PatronRecords
603 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Arkansas
Eric Schaefer
Hematology & Oncology · Fayetteville, AR
Frits Van Rhee
Hematology & Oncology · Little Rock, AR
Isam Abdel-Karim
Hematology & Oncology · Fort Smith, AR
Appalanaidu Sasapu
Hematology & Oncology · Little Rock, AR
Stephan Rosenfeld
Hematology & Oncology · Fayetteville, AR
Stephen Divers
Hematology & Oncology · Hot Springs, AR
Related records
Hematology & Oncology in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.